Proton MRS in mild cognitive impairment

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Mild cognitive impairment (MCI) is a clinical syndrome operationalized for early diagnosis and treatment of Alzheimer's disease (AD). Many individuals with MCI are at the prodromal stage of AD or other dementia. Various quantitative magnetic resonance imaging (MRI) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures for early diagnosis and disease progression in MCI. The pathology underlying MCI is heterogeneous, dominated by AD, cerebrovascular disease, Lewy body disease, or a mixture of these pathologies in autopsy cohorts. Proton magnetic resonance spectroscopy ( 1H MRS) metabolite markers may help identify and track etiologies that typically underlie MCI in the elderly. The role of proton MRS will be critical for pathophysiological processes for which a reliable biomarker does not exist such as neuronal dysfunction, glial and microglial activation in MCI.

Original languageEnglish (US)
Pages (from-to)770-777
Number of pages8
JournalJournal of Magnetic Resonance Imaging
Volume37
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Protons
Alzheimer Disease
Early Diagnosis
Pathology
Prodromal Symptoms
Cerebrovascular Disorders
Lewy Body Disease
Neuroglia
Dementia
Disease Progression
Cognitive Dysfunction
Autopsy
Biomarkers
Magnetic Resonance Imaging
Proton Magnetic Resonance Spectroscopy
Therapeutics

Keywords

  • Alzheimer's disease
  • dementia
  • magnetic resonance spectroscopy
  • mild cognitive impairment

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Proton MRS in mild cognitive impairment. / Kantarci, Kejal M.

In: Journal of Magnetic Resonance Imaging, Vol. 37, No. 4, 04.2013, p. 770-777.

Research output: Contribution to journalArticle

@article{ac6b0ffa98f84237abee562facd1206a,
title = "Proton MRS in mild cognitive impairment",
abstract = "Mild cognitive impairment (MCI) is a clinical syndrome operationalized for early diagnosis and treatment of Alzheimer's disease (AD). Many individuals with MCI are at the prodromal stage of AD or other dementia. Various quantitative magnetic resonance imaging (MRI) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures for early diagnosis and disease progression in MCI. The pathology underlying MCI is heterogeneous, dominated by AD, cerebrovascular disease, Lewy body disease, or a mixture of these pathologies in autopsy cohorts. Proton magnetic resonance spectroscopy ( 1H MRS) metabolite markers may help identify and track etiologies that typically underlie MCI in the elderly. The role of proton MRS will be critical for pathophysiological processes for which a reliable biomarker does not exist such as neuronal dysfunction, glial and microglial activation in MCI.",
keywords = "Alzheimer's disease, dementia, magnetic resonance spectroscopy, mild cognitive impairment",
author = "Kantarci, {Kejal M}",
year = "2013",
month = "4",
doi = "10.1002/jmri.23800",
language = "English (US)",
volume = "37",
pages = "770--777",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Proton MRS in mild cognitive impairment

AU - Kantarci, Kejal M

PY - 2013/4

Y1 - 2013/4

N2 - Mild cognitive impairment (MCI) is a clinical syndrome operationalized for early diagnosis and treatment of Alzheimer's disease (AD). Many individuals with MCI are at the prodromal stage of AD or other dementia. Various quantitative magnetic resonance imaging (MRI) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures for early diagnosis and disease progression in MCI. The pathology underlying MCI is heterogeneous, dominated by AD, cerebrovascular disease, Lewy body disease, or a mixture of these pathologies in autopsy cohorts. Proton magnetic resonance spectroscopy ( 1H MRS) metabolite markers may help identify and track etiologies that typically underlie MCI in the elderly. The role of proton MRS will be critical for pathophysiological processes for which a reliable biomarker does not exist such as neuronal dysfunction, glial and microglial activation in MCI.

AB - Mild cognitive impairment (MCI) is a clinical syndrome operationalized for early diagnosis and treatment of Alzheimer's disease (AD). Many individuals with MCI are at the prodromal stage of AD or other dementia. Various quantitative magnetic resonance imaging (MRI) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures for early diagnosis and disease progression in MCI. The pathology underlying MCI is heterogeneous, dominated by AD, cerebrovascular disease, Lewy body disease, or a mixture of these pathologies in autopsy cohorts. Proton magnetic resonance spectroscopy ( 1H MRS) metabolite markers may help identify and track etiologies that typically underlie MCI in the elderly. The role of proton MRS will be critical for pathophysiological processes for which a reliable biomarker does not exist such as neuronal dysfunction, glial and microglial activation in MCI.

KW - Alzheimer's disease

KW - dementia

KW - magnetic resonance spectroscopy

KW - mild cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=84875465982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875465982&partnerID=8YFLogxK

U2 - 10.1002/jmri.23800

DO - 10.1002/jmri.23800

M3 - Article

C2 - 23526756

AN - SCOPUS:84875465982

VL - 37

SP - 770

EP - 777

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 4

ER -